蛋白S异常与血栓形成的人群规模研究
本研究利用英国生物银行(n=426 436)和美国All of Us(n=204 006)两个人群队列,评估PROS1罕见胚系变异及血浆蛋白S水平与血栓表型的关联。结果显示,最高风险PROS1变异(FIS=1.0)杂合携带者静脉血栓栓塞风险显著升高(OR 14.01;95%CI 6.98-27.14;P=9.09×10⁻¹¹),且其总蛋白S水平仅为正常值的48.0%;而FIS≥0.7的错义变异风险较低(OR 1.977;95%CI 1.552-2.483;P=1.95×10⁻⁷)。PROS1编码变异与心肌梗死、外周动脉疾病和非心源性缺血性卒中无关,但血浆蛋白S缺乏与静脉血栓栓塞及外周动脉疾病显著相关,且与PROS1变异携带状态无关。结论提示,PROS1功能丧失是比既往认识更强的静脉血栓栓塞风险因素,而循环蛋白S缺乏更可能由获得性、环境或反式遗传因素导致。
要点
- PROS1最高风险变异(FIS=1.0)杂合携带者VTE风险显著升高(OR 14.01;95%CI 6.98-27.14;P=9.09×10⁻¹¹),携带者总蛋白S水平为正常值的48.0%。
- PROS1错义变异(FIS≥0.7)VTE风险较低(OR 1.977;95%CI 1.552-2.483;P=1.95×10⁻⁷),血浆蛋白S浓度仅轻度降低。
- PROS1编码变异与心肌梗死、外周动脉疾病和非心源性缺血性卒中三种动脉血栓均无显著关联。
- 血浆蛋白S缺乏与VTE及外周动脉疾病显著相关,且与PROS1变异携带状态无关,提示获得性或反式因素更可能导致蛋白S缺乏。
- PROS1功能丧失相关的VTE风险在Kaplan-Meier分析中持续终生(log-rank P=0.0005)。
适用人群与场景
- 英国生物银行队列:n=426 436,2006-2010年入组,末次随访2020年5月19日,接受全外显子测序,其中n=44 431有高通量血浆蛋白质组学蛋白S水平测量;54.3%女性,中位年龄58.3岁(IQR 50.5-63.7),95.6%为欧洲 ancestry,18 011例曾发生VTE。
- 美国All of Us队列:n=204 006,2017年开始招募且仍在进行,接受胚系全基因组测序。
诊断标准与关键阈值
- PROS1变异按功能影响评分(FIS)分层:FIS=1.0包括无义、移码和必需剪接位点破坏;FIS≥0.7包括错义变异。
- FIS=1.0变异调整后患病率:英国0.0091%,美国0.0178%;FIS≥0.7变异调整后患病率:英国0.22%,美国0.20%。
研究设计与关键结果
- 研究设计:横断面研究,使用英国生物银行(n=426 436)和美国All of Us(n=204 006)纵向人群队列。
- 暴露:PROS1罕见胚系变异,按FIS分层;主要终点:低血浆蛋白S水平及PROS1变异与一系列血栓表型的关联,采用Firth逻辑回归和线性回归建模。
- FIS=1.0变异杂合携带者VTE风险显著升高(OR 14.01;95%CI 6.98-27.14;P=9.09×10⁻¹¹);携带者总蛋白S水平为正常值的48.0%(与非携带者相比P=0.02)。
- FIS≥0.7错义变异与轻度降低的血浆蛋白S浓度相关,VTE风险点估计较小(OR 1.977;95%CI 1.552-2.483;P=1.95×10⁻⁷)。
- 两个FIS截断值下PROS1与VTE的关联在All of Us队列中独立验证,效应量相似。
- PROS1编码变异与心肌梗死、外周动脉疾病和非心源性缺血性卒中三种动脉血栓均无显著关联。
- PROS1变异与低血浆蛋白S水平相关性差;血浆蛋白S缺乏与VTE及外周动脉疾病显著相关,且与PROS1变异携带状态无关。
- Kaplan-Meier生存分析显示PROS1胚系功能丧失相关的VTE风险升高(log-rank P=0.0005),且似乎持续终生。
证据类型、等级与局限
- 证据类型:横断面研究,使用两个大型人群队列(英国生物银行和美国All of Us)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,PROS1真正的遗传性功能丧失罕见,但作为一般人群中VTE的风险因素比既往认识更强。
- 作者认为,获得性、环境或反式遗传因素比PROS1编码变异更可能导致循环蛋白S缺乏,且低血浆蛋白S与VTE相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Clinical decision-making in thrombotic disorders is impeded by long-standing uncertainty regarding the magnitude of venous and arterial thrombosis risk associated with low protein S. Population-scale multiomic datasets offer an unprecedented opportunity to answer questions regarding the epidemiology and clinical impacts of protein S deficiency.
OBJECTIVE: To evaluate the risk associated with protein S deficiency across multiple thrombosis phenotypes.
DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study using longitudinal population cohorts derived from the UK Biobank (n = 426 436) and the US National Institutes of Health All of Us (n = 204 006) biorepositories. UK Biobank participants were enrolled in 2006-2010 (last follow-up, May 19, 2020) and underwent whole exome sequencing, with a subset (n = 44 431) having protein S levels measured by high-throughput plasma proteomics. Recruitment for All of Us began in 2017 and is ongoing, with participants receiving germline whole genome sequencing. Both cohorts include individual-level data on demographics, laboratory measurements, and clinical outcomes.
EXPOSURE: Presence of rare germline genetic variants in PROS1, segmented by functional impact score (FIS), an in silico prediction of the probability that a genetic variant will disrupt protein activity.
MAIN OUTCOMES AND MEASURES: Firth logistic regression and linear regression modeling were used to evaluate the thrombosis risk associated with low plasma protein S levels and PROS1 variants across a range of FIS ratings.
RESULTS: The UK Biobank cohort was 54.3% female, with a median age of 58.3 (IQR, 50.5-63.7) years at enrollment. Most participants (95.6%) were of European ancestry, and 18 011 had experienced a venous thromboembolism (VTE). In this population cohort, heterozygosity for the highest-risk PROS1 variants with an FIS of 1.0 (nonsense, frameshift, and essential splice site disruptions) was rare (adjusted prevalence, 0.0091% in the UK and 0.0178% in the US) and associated with markedly increased risk of VTE (odds ratio [OR], 14.01; 95% CI, 6.98-27.14; P = 9.09 × 10-11). Plasma proteomics (n = 44 431) demonstrated that carriers of these variants had total protein S levels that were 48.0% of normal (P = .02 compared with noncarriers). In contrast, less damaging missense variants (FIS ≥0.7) occurred more commonly (adjusted prevalence, 0.22% in the UK and 0.20% in the US) and were associated with marginally reduced plasma protein S concentrations and a smaller point estimate for VTE risk (OR, 1.977; 95% CI, 1.552-2.483; P = 1.95 × 10-7). Associations between PROS1 and VTE at both FIS cutoffs were independently validated in the All of Us cohort with similar effect sizes. No association was detected between the presence of coding PROS1 variants and 3 forms of arterial thrombosis: myocardial infarction, peripheral artery disease, and noncardioembolic ischemic stroke. The presence of PROS1 variants correlated poorly with low plasma protein S levels, and protein S deficiency was significantly associated with VTE and peripheral artery disease regardless of PROS1 variant carrier status. The elevated risk of VTE associated with germline loss of function in PROS1 was evident in Kaplan-Meier survival analysis and appeared to persist throughout life (log-rank P = .0005).
CONCLUSIONS AND RELEVANCE: True inherited loss of function in PROS1 is rare but represents a stronger risk factor for VTE in the general population than previously understood. Acquired, environmental, or trans-acting genetic factors are more likely to cause circulating protein S deficiency than coding variation in PROS1, and low plasma protein S is associated with VTE.
参考来源
- Chaudhry SA, Haj AK, Ryu J, et al. Population-Scale Studies of Protein S Abnormalities and Thrombosis. JAMA. 2025. PMID: 40029645. doi:10.1001/jama.2025.0155
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。